ギラン・バレー症候群治療薬の世界市場レポート 2025年

ギラン・バレー症候群治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.9％で17億1,000万米ドルに成長します。予測期間の成長は、ギラン・バレー症候群（GBS）の罹患率の増加、認知・認定率の上昇、老人人口の増加、病院薬局や小売薬局の役割の増加、経口薬や非経口薬の需要増などに起因すると考えられます。予測期間における主な動向としては、新しい治療法の開発、診断ツールの進歩、製薬会社と研究開発機関の連携、遺伝子治療の進歩、免疫グロブリン静注療法の進歩などが挙げられます。

個別化医療に対する需要の急増が予想され、ギラン・バレー症候群治療薬市場の成長を牽引するとみられます。個別化医療は、遺伝学やライフスタイルなどの個人の特性に基づいて治療をカスタマイズし、効果を最適化し副作用を最小限に抑えるものです。この需要は、より効率的な治療の可能性、ゲノミクスの進歩、疾病の複雑化、規制の後ろ盾によって促進されています。ギラン・バレー症候群（GBS）の場合、個別化医療は、個々の患者のプロファイルに応じて治療を調整し、治療成績を向上させ、副作用を軽減することを目的としています。例えば、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）の報告によると、2024年2月、FDAは希少疾患に対する新規の個別化治療を16件承認し、2022年の6件から増加しました。この動向は、個別化医療への嗜好の高まりがギラン・バレー症候群治療薬市場の成長を後押ししていることを裏付けています。

ギラン・バレー症候群治療薬市場の主なプレーヤーは、市場での存在感を維持するために、ヒト化モノクローナル抗体などの製品を開発することで革新を進めています。ヒト化モノクローナル抗体は、ヒト抗体とマウスやラットのモノクローナル抗体の一部を結合させた実験室で作られる抗体です。ヒト化モノクローナル抗体は、GBS病態に関与する特定の免疫系成分を標的とすることができるため、潜在的な治療薬として検討されています。例えば、2023年10月、米国のバイオ医薬品会社であるアネクソン社は、ANX005がGBS治療薬として欧州医薬品庁（EMA）およびFDAから希少疾病用医薬品の指定を受けたと発表しました。ANX005はヒト化モノクローナル抗体で、C1qを阻害することにより、初期段階のGBSにおける補体を介した炎症と神経細胞障害を阻止します。アネクソンは、GBSを対象としたANX005の第3相臨床試験の目標症例登録を完了し、2024年前半にトップラインデータが得られる見込みです。ANX005は、神経系におけるC1q活性を選択的に阻害することにより炎症と神経障害を緩和し、GBS患者における自己免疫障害の迅速な停止と筋力回復を促進することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ギラン・バレー症候群治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のギラン・バレー症候群治療薬市場：成長率分析
• 世界のギラン・バレー症候群治療薬市場の実績：規模と成長, 2019-2024
• 世界のギラン・バレー症候群治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ギラン・バレー症候群治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のギラン・バレー症候群治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫グロブリン（IVIG）
• コルチコステロイド
• 血漿交換
• 世界のギラン・バレー症候群治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一選択治療
• 補助的または支持的な治療
• 世界のギラン・バレー症候群治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• その他の用途
• 世界のギラン・バレー症候群治療薬市場免疫グロブリン（IVIG）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内免疫グロブリン（IVIG）療法
• ヒト正常免疫グロブリン（HNIG）
• 高度免疫グロブリン製剤
• GBS治療のためのIVIG製剤
• IVIG治療の一環としてのモノクローナル抗体
• 世界のギラン・バレー症候群治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メチルプレドニゾロン
• プレドニゾロン
• デキサメタゾン
• ヒドロコルチゾン
• ベタメタゾン
• 経口コルチコステロイド製剤
• 世界のギラン・バレー症候群治療薬市場血漿交換のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療的血漿交換（TPE）
• GBS治療のための血漿交換装置
• 遠心血漿交換
• 免疫吸着血漿交換
• 自己血漿交換（APE）

第7章 地域別・国別分析

• 世界のギラン・バレー症候群治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のギラン・バレー症候群治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ギラン・バレー症候群治療薬市場：競合情勢
• ギラン・バレー症候群治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Grifols SA
• Octapharma AG
• Cadila Healthcare Limited
• Argenx SE
• Alnylam Pharmaceuticals Inc.
• Biotest AG
• CSL Behring LLC
• Kedrion Biopharma Inc.
• Cellenkos Inc.
• Annexon Inc.
• Hansa Medical AB
• Akari Therapeutics Plc
• Alexion Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ギラン・バレー症候群治療薬市場2029：新たな機会を提供する国
• ギラン・バレー症候群治療薬市場2029：新たな機会を提供するセグメント
• ギラン・バレー症候群治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Guillain-Barre syndrome drugs are medications designed to address the symptoms and complications associated with Guillain-Barre syndrome (GBS), an autoimmune condition characterized by the immune system attacking the nervous system. These drugs primarily target modulating the activity of the peripheral immune system to slow down the disease's progression and alleviate its symptoms.

The primary classes of Guillain-Barre syndrome drugs include immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication derived from pooled human blood plasma containing a high concentration of antibodies. It is used as a first-line treatment and in adjunctive or supportive therapy, finding widespread use in clinics, hospitals, and other medical settings.

The Guillain-Barre syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides Guillain-Barre syndrome drugs market statistics, including Guillain-Barre syndrome drugs industry global market size, regional shares, competitors with a Guillain-Barre syndrome drugs market share, detailed Guillain-Barre syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Guillain-Barre syndrome drugs industry. This Guillain-Barre syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The guillain-barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services.

The guillain-barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy.

The expected surge in demand for personalized medicine is set to drive growth in the Guillain-Barre syndrome drugs market. Personalized medicine involves customizing medical treatments based on individual characteristics such as genetics or lifestyle to optimize effectiveness and minimize side effects. This demand is fueled by the potential for more efficient treatments, advancements in genomics, the increasing complexity of diseases, and regulatory backing. In Guillain-Barre syndrome (GBS), personalized medicine aims to tailor treatments according to individual patient profiles, improving therapeutic outcomes and reducing adverse effects. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, as reported by the US-based non-profit organization, Personalized Medicine Coalition. This trend underscores how the rising preference for personalized medicine is pushing growth in the Guillain-Barre syndrome drugs market.

Key players in the guillain-barre syndrome drugs market are innovating by developing products such as humanized monoclonal antibodies to maintain their market presence. Humanized monoclonal antibodies are lab-made antibodies that combine human antibodies with parts of mouse or rat monoclonal antibodies. They are explored as potential therapies due to their ability to target specific immune system components involved in GBS pathology. For example, in October 2023, Annexon Inc., a US-based biopharmaceutical company, announced that ANX005 received orphan drug designation from the European Medicines Agency (EMA) and the FDA for GBS treatment. ANX005, a humanized monoclonal antibody, works by inhibiting C1q to halt complement-mediated inflammation and neuronal damage in early-stage GBS. Annexon has completed target enrollment in a Phase 3 trial of ANX005 in GBS, with top-line data expected in the first half of 2024. ANX005 aims to mitigate inflammation and nerve damage by selectively blocking C1q activity in the nervous system, promoting rapid cessation of autoimmune damage and muscle strength recovery in GBS patients.

In April 2022, Grifols SA, a Spanish pharmaceutical company, acquired Biotest AG for $1.17 billion, aiming to expand and diversify its plasma supply. This strategic move also strengthens Grifols' presence and revenues in Europe, the Middle East, and Africa, while fostering collaboration between Grifols and Biotest to improve global access to plasma-derived therapies. Biotest AG, based in Germany, provides drugs for Guillain-Barre syndrome (GBS) treatment.

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

North America was the largest region in the Guillain-Barre syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the guillain-barre syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Guillain-Barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Guillain-Barre Syndrome Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on guillain-barre syndrome drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for guillain-barre syndrome drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The guillain-barre syndrome drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Immunoglobulins (IVIG); Corticosteroids; Plasma Exchange
• 2) By Treatment Type: First-Line Treatment; Adjunctive Or Supportive Treatment
• 3) By Application: Clinic; Hospital; Other Applications
• Subsegments:
• 1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy; Human Normal Immunoglobulin (Hnig); Hyperimmune Immunoglobulin Products; Ivig Formulations For Gbs Treatment; Monoclonal Antibodies As Part Of Ivig Treatment
• 2) By Corticosteroids: Methylprednisolone; Prednisolone; Dexamethasone; Hydrocortisone; Betamethasone; Oral Corticosteroid Formulations
• 3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe); Plasmapheresis Equipment For Gbs Treatment; Centrifugal Plasma Exchange; Immunoadsorption Plasma Exchange; Autologous Plasma Exchange (Ape)
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Guillain-Barre Syndrome Drugs Market Characteristics

3. Guillain-Barre Syndrome Drugs Market Trends And Strategies

4. Guillain-Barre Syndrome Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Guillain-Barre Syndrome Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Guillain-Barre Syndrome Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Guillain-Barre Syndrome Drugs Market Growth Rate Analysis
• 5.4. Global Guillain-Barre Syndrome Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Guillain-Barre Syndrome Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Guillain-Barre Syndrome Drugs Total Addressable Market (TAM)

6. Guillain-Barre Syndrome Drugs Market Segmentation

• 6.1. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulins (IVIG)
• Corticosteroids
• Plasma Exchange
• 6.2. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Treatment
• Adjunctive Or Supportive Treatment
• 6.3. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other Applications
• 6.4. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Immunoglobulin (IVIG) Therapy
• Human Normal Immunoglobulin (HNIG)
• Hyperimmune Immunoglobulin Products
• IVIG Formulations For GBS Treatment
• Monoclonal Antibodies As Part Of IVIG Treatment
• 6.5. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methylprednisolone
• Prednisolone
• Dexamethasone
• Hydrocortisone
• Betamethasone
• Oral Corticosteroid Formulations
• 6.6. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Plasma Exchange (TPE)
• Plasmapheresis Equipment For GBS Treatment
• Centrifugal Plasma Exchange
• Immunoadsorption Plasma Exchange
• Autologous Plasma Exchange (APE)

7. Guillain-Barre Syndrome Drugs Market Regional And Country Analysis

• 7.1. Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Guillain-Barre Syndrome Drugs Market

• 8.1. Asia-Pacific Guillain-Barre Syndrome Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Guillain-Barre Syndrome Drugs Market

• 9.1. China Guillain-Barre Syndrome Drugs Market Overview
• 9.2. China Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Guillain-Barre Syndrome Drugs Market

• 10.1. India Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Guillain-Barre Syndrome Drugs Market

• 11.1. Japan Guillain-Barre Syndrome Drugs Market Overview
• 11.2. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Guillain-Barre Syndrome Drugs Market

• 12.1. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Guillain-Barre Syndrome Drugs Market

• 13.1. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Guillain-Barre Syndrome Drugs Market

• 14.1. South Korea Guillain-Barre Syndrome Drugs Market Overview
• 14.2. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Guillain-Barre Syndrome Drugs Market

• 15.1. Western Europe Guillain-Barre Syndrome Drugs Market Overview
• 15.2. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Guillain-Barre Syndrome Drugs Market

• 16.1. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Guillain-Barre Syndrome Drugs Market

• 17.1. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Guillain-Barre Syndrome Drugs Market

• 18.1. France Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Guillain-Barre Syndrome Drugs Market

• 19.1. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Guillain-Barre Syndrome Drugs Market

• 20.1. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Guillain-Barre Syndrome Drugs Market

• 21.1. Eastern Europe Guillain-Barre Syndrome Drugs Market Overview
• 21.2. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Guillain-Barre Syndrome Drugs Market

• 22.1. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Guillain-Barre Syndrome Drugs Market

• 23.1. North America Guillain-Barre Syndrome Drugs Market Overview
• 23.2. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Guillain-Barre Syndrome Drugs Market

• 24.1. USA Guillain-Barre Syndrome Drugs Market Overview
• 24.2. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Guillain-Barre Syndrome Drugs Market

• 25.1. Canada Guillain-Barre Syndrome Drugs Market Overview
• 25.2. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Guillain-Barre Syndrome Drugs Market

• 26.1. South America Guillain-Barre Syndrome Drugs Market Overview
• 26.2. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Guillain-Barre Syndrome Drugs Market

• 27.1. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Guillain-Barre Syndrome Drugs Market

• 28.1. Middle East Guillain-Barre Syndrome Drugs Market Overview
• 28.2. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Guillain-Barre Syndrome Drugs Market

• 29.1. Africa Guillain-Barre Syndrome Drugs Market Overview
• 29.2. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Guillain-Barre Syndrome Drugs Market Competitive Landscape And Company Profiles

• 30.1. Guillain-Barre Syndrome Drugs Market Competitive Landscape
• 30.2. Guillain-Barre Syndrome Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Guillain-Barre Syndrome Drugs Market Other Major And Innovative Companies

• 31.1. Biogen Inc.
• 31.2. Chugai Pharmaceutical Co. Ltd.
• 31.3. Grifols SA
• 31.4. Octapharma AG
• 31.5. Cadila Healthcare Limited
• 31.6. Argenx SE
• 31.7. Alnylam Pharmaceuticals Inc.
• 31.8. Biotest AG
• 31.9. CSL Behring LLC
• 31.10. Kedrion Biopharma Inc.
• 31.11. Cellenkos Inc.
• 31.12. Annexon Inc.
• 31.13. Hansa Medical AB
• 31.14. Akari Therapeutics Plc
• 31.15. Alexion Pharmaceuticals Inc.

32. Global Guillain-Barre Syndrome Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market

34. Recent Developments In The Guillain-Barre Syndrome Drugs Market

35. Guillain-Barre Syndrome Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Guillain-Barre Syndrome Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Guillain-Barre Syndrome Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Guillain-Barre Syndrome Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer